Biotie neurology, hepatic news
After Biotie completed a portfolio review, the biotech said it will seek further opportunities like its June deal for an exclusive option to acquire Neurelis Inc. (Encinitas, Calif.). Biotie believes Neurelis' lead product NRL-1 will give the biotech access to a "significant commercial opportunity in the U.S. that could be accessed via a small, specialist sales force." NRL-1 is an intranasal formulation of diazepam in Phase I testing to treat breakthrough seizures associated with epilepsy. Biotie said it expects to exercise its option next half following discussions with FDA (see BioCentury, June 10).
Biotie also decided to conduct a Phase II trial with BTT-1023 for primary sclerosing cholangitis, a rare fibrotic disease of the liver. The company said it is in advanced discussions for non-dilutive co-funding for the trial. BTT-1023 is a human mAb against vascular adhesion protein-1 (VAP-1; SSAO). Biotie also said that discussions for a potential partnership for SYN120 are at an advanced stage. The oral serotonin (5-HT6) receptor antagonist completed Phase I testing for Alzheimer's disease (AD) and is ready for Phase II testing. ...